Wuhan BravoVax Co., Ltd.
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation, RCVi) at low, medium, and high doses in healthy adults (previously primed with authorized vaccines).
COVID-19
Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 60 participants |
Masking : | None (Open Label) |
Primary Purpose : | Prevention |
Official Title : | A Single-arm, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine (Adenovirus Vector) for Inhalation in People 21 to 65 Years Old (Previously Primed With Authorized Vaccines) |
Actual Study Start Date : | June 2023 |
Estimated Primary Completion Date : | December 2023 |
Estimated Study Completion Date : | July 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Low dose 21~65 year old healthy subjects, received low dose of RCVi |
Biological: Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation |
Experimental: Medium dose 21~65 year old healthy subjects, received medium dose of RCVi |
Biological: Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation |
Experimental: High dose 21~65 year old healthy subjects, received high dose of RCVi |
Biological: Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation |
Ages Eligible for Study: | 21 Years to 65 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
National University Hospital
Singapore, Singapore,